As of Jan. 29, the FDA has approved more than a dozen glucagon-like peptide-1 receptor agonists for diabetes, weight loss, cardiovascular disease and other indications.

Recent research highlights a trend of high discontinuation rates among patients using glucagon-like peptide-1 receptor agonists for Type 2 diabetes and weight loss. A large cohort study examining ...

Dozens of unethical peddlers are hawking glucagon-like peptide-1 agonists (GLP-1s) on the Internet. They are evading scrutiny by the U.S. Food and Drug Administration (FDA) and operating outside ...

To evaluate the effect of combination therapy with pioglitazone and glucagon-like peptide (GLP)-1 in patients with type 2 diabetes. Conclusions: GLP-1 and pioglitazone show an additive glucose ...

As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a new study has uncovered neurological and behavioral health benefits amid increased risks for ...

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...

Read our takeaways from the UBS Evidence Lab survey on key trends in GLP-1 consumer behaviour GLP-1s, also known as glucagon-like peptide 1, have been on the market for almost 20 years – the ...

including glucagon-like peptide (GLP)-1, are peptide hormones responsible for the 'incretin effect', a phenomenon in which where more insulin is secreted in response to glucose ingested during a ...

A new study reports that GLP-1 medications may provide benefits to cognitive and behavioral health, including lowered addiction risk. Scientists also confirmed that the use of these medications ...

glucagon-like peptide-1 (GLP-1), and glucagon receptors — experienced the greatest weight loss reductions among the agents studied. Data derived from; Moiz A, et al. Ann Intern Med. 2024 ...

Share on Pinterest A new study compares the risks and benefits of using GLP-1 medications. Iuliia Burmistrova/Getty Images The use of glucagon-like peptide-1 receptor agonists (GLP-1 agonists) for ...